The U.S. Supreme Court rejected Merck & Co. Inc.’s bid to revive a $2.54 billion jury verdict the company won against rival drugmaker Gilead Sciences Inc. for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

Gilead Sciences Inc. bolstered the company’s capabilities in treating liver diseases with a €1.15 billion ($1.4 billion) cash acquisition of Germany-based Myr GmbH, which is focused on developing therapies for the treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis.

Three scientists will share the Nobel Prize for Medicine for their seminal discoveries that led to the identification of the Hepatitis C virus, a significant health problem across the globe that can lead to cirrhosis and liver cancer in patients.

As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.

The U.S. Food and Drug Administration approved Gilead Sciences’ Epclusa for hepatitis C (HCV) for use in children as young as 6 years of age or who weigh at least 17 kilograms.

An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.

Spring Bank Pharmaceuticals, based in Hopkinton, Massachusetts, is discontinuing development of inarigivir soproxil for chronic hepatitis B virus (HBV).

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.

Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.

A U.S. appeals court dealt a major blow to Merck & Co. Inc., upholding a ruling that threw out a $2.54 billion (£1.97 billion) jury verdict the drugmaker had won against Gilead Sciences Inc.